The Public Summary Documents for the initial rejections and deferrals from the March 2014 PBAC meeting have been added to MAESTrO Australia PBAC:

• Fentanyl citrate (Abstral)
• Fentanyl pectin (PecFent)
• Fluticasone furoate with vilanterol trifenatate (Breo Ellipta)
• Indacaterol maleate with glycopyrronium bromide (Ultibro Breezhaler)
• Lurasidone hydrochloride (Latuda)
• Trametinib dimethyl sulfoxide (Mekinist)
• Vilanterol trifenatate with umeclidinium bromide (Anoro Ellipta)
• Crizotinib (Xalkori)
• Pertuzumab (Perjeta)
• Ranibizumab (Lucentis)
• Trastuzumab emtansine (Kadcyla)
• Zoster virus vaccine (Zostavax)